Injectable Magnesium Chloride Recalled Due to Facility Contamination Concerns
Pharmacy Innovations is recalling magnesium chloride hexahydrate injectable (5 mL vials) distributed nationwide due to insanitary facility conditions that compromise product sterility assurance.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a sterile injectable product. FDA inspection revealed insanitary facility conditions that compromise sterility assurance. No illnesses or injuries have been reported, but this qualifies as a risk-of-harm product where infection could result if contaminated product reaches patients.
Plain-English summary
Pharmacy Innovations is recalling magnesium chloride hexahydrate injectable solution (200 mg/mL, 5 mL vials) distributed nationwide. The product is a prescription injectable medication.
FDA inspection of the manufacturing facility identified insanitary conditions. These conditions create a lack of assurance regarding the sterility of the product. Sterile injectables contaminated with bacteria or other microorganisms can cause serious infections in patients, including sepsis and other life-threatening complications.
Healthcare providers and patients who have or may have received this product should consult their healthcare provider about whether they have been affected. Patients should not discontinue use of their prescribed medication without medical guidance. Healthcare facilities should verify whether affected units (code t20221011@36) were received and follow appropriate protocols for secure disposal or return to the manufacturer.
The recalled product
- Product
- MAGNESIUM CHLORIDE HEXAHYDRATE-PF- 200MG/ML (5ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable / Intravenous
- Hazard
- sterility-compromise
- facility-contamination
- bacterial-infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221011@36
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27